Anthony Patron

“I'll stick to one and maybe go back to Vijay, which is maybe capital allocation and diabetes. There will be a pretty significant hole in the portfolio. It's also growth accretive based on the quarterly numbers for this fiscal quarter.”

“A couple on type 2 non-insulin intensive. We're hearing from, you know, some docs in the field there that potentially the coverage decision could have some, you know, requirements around it, specifically around A1C verification at various increments, let's say three, six months, nine months.”

“And then just quick on MVP, Vascade, you know, all of the PFA companies reported here. It looks like the market, you know, for cardiac ablation slowed a little bit in 1Q. You know, just from the vantage point of humanetics, where does it see just the underlying, you know, market for EP volumes?”

“Just one on the RCT and just looking at some of the historical data out there.”